GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gland Pharma Ltd (NSE:GLAND) » Definitions » Forward PE Ratio

Gland Pharma (NSE:GLAND) Forward PE Ratio : 0.00 (As of Jun. 06, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Gland Pharma Forward PE Ratio?

Gland Pharma's Forward PE Ratio for today is 0.00.

Gland Pharma's PE Ratio without NRI for today is 40.18.

Gland Pharma's PE Ratio for today is 40.18.


Gland Pharma Forward PE Ratio Historical Data

The historical data trend for Gland Pharma's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gland Pharma Forward PE Ratio Chart

Gland Pharma Annual Data
Trend 2021-10
Forward PE Ratio
51.28

Gland Pharma Quarterly Data
Forward PE Ratio

Competitive Comparison of Gland Pharma's Forward PE Ratio

For the Drug Manufacturers - General subindustry, Gland Pharma's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gland Pharma's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gland Pharma's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Gland Pharma's Forward PE Ratio falls into.



Gland Pharma Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Gland Pharma  (NSE:GLAND) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Gland Pharma Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Gland Pharma's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Gland Pharma (NSE:GLAND) Business Description

Traded in Other Exchanges
Address
Plot No. 11 and 84, TSIIC Phase: IV, Pashamylaram (V), Patancheru (M), Sangareddy District, Hyderabad, TG, IND, 502307
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Further, the group is involved in vast range of therapeutic categories that include Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarial, Cardiology and more - to Hormones and related Drugs, Fertility Supplements and Gnrh Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA.

Gland Pharma (NSE:GLAND) Headlines

No Headlines